Richard Frank, MD, MHSA

A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.

FDA approval of orforglipron may expand access to obesity treatment by offering a more convenient oral GLP-1 therapy option.

Explore the differences between oral and injectable semaglutide for weight management, focusing on adherence, adverse effects, and patient preferences.